Conivaptan HClCAS# 168626-94-6 |
- Mozavaptan
Catalog No.:BCC5095
CAS No.:137975-06-5
- Tolvaptan
Catalog No.:BCC5096
CAS No.:150683-30-0
- Desmopressin
Catalog No.:BCC1525
CAS No.:16679-58-6
- Desmopressin Acetate
Catalog No.:BCC1526
CAS No.:62288-83-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 168626-94-6 | SDF | Download SDF |
| PubChem ID | 216322 | Appearance | Powder |
| Formula | C32H27ClN4O2 | M.Wt | 535.04 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | YM 087 | ||
| Solubility | DMSO : ≥ 100 mg/mL (186.90 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[4-(2-methyl-4,5-dihydro-3H-imidazo[4,5-d][1]benzazepine-6-carbonyl)phenyl]-2-phenylbenzamide;hydrochloride | ||
| SMILES | CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6.Cl | ||
| Standard InChIKey | BTYHAFSDANBVMJ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C32H26N4O2.ClH/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22;/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Conivaptan (hydrochloride) is a non-peptide antagonist of vasopressin receptor, with Ki values of 0.48 and 3.04 nM for rat liver V1A receptor and rat kidney V2 receptor respectively.In Vivo:Conivaptan (0.03, 0.1 and 0.3 mg/kg, i.v.) dose-dependently increases urine volume and reduces urine osmolality in both myocardial infarction and sham-operated rats. Conivaptan (0.3 mg/kg i.v.) significantly reduces right ventricular systolic pressure, left ventricular end-diastolic pressure, lung/body weight and right atrial pressure in myocardial infarction rats. Conivaptan (0.3 mg/kg i.v.) significantly increases dP/dt(max)/left ventricular pressure in myocardial infarction rats[1]. Conivaptan produces an acute increase in urine volume (UV), a reduction in osmolality (UOsm) and, at the end of the investigation, cirrhotic rats receiving the V(1a)/V(2)-AVP receptor antagonist does not show hyponatremia or hypoosmolality. Conivaptan also normalizes U(Na)V without affecting creatinine clearance and arterial pressure[2]. Conivaptan (0.01 to 0.1 mg/kg, i.v.) exerts a dose-dependent diuretic effect in dogs without an increase in the urinary excretion of electrolytes, inhibits the pressor effect of exogenous vasopressin in a dose-dependent manner (0.003 to 0.1 mg/kg i.v.) and, at the highest dose (0.1 mg/kg i.v.), almost completely blocks vasoconstriction caused by exogenous vasopressin. Conivaptan (0.1 mg/kg, i.v.) improves cardiac function, as evidenced by significant increases in left ventricular dP/dtmax, cardiac output and stroke volume, and reduces preload and afterload, as evidenced by significant decreases in left ventricular end-diastolic pressure and total peripheral vascular resistance in dogs with congestive heart failure[3]. References: | |||||
Conivaptan HCl Dilution Calculator
Conivaptan HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.869 mL | 9.3451 mL | 18.6902 mL | 37.3804 mL | 46.7255 mL |
| 5 mM | 0.3738 mL | 1.869 mL | 3.738 mL | 7.4761 mL | 9.3451 mL |
| 10 mM | 0.1869 mL | 0.9345 mL | 1.869 mL | 3.738 mL | 4.6725 mL |
| 50 mM | 0.0374 mL | 0.1869 mL | 0.3738 mL | 0.7476 mL | 0.9345 mL |
| 100 mM | 0.0187 mL | 0.0935 mL | 0.1869 mL | 0.3738 mL | 0.4673 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Conivaptan Hydrochloride is a non-peptide inhibitor of antidiuretic hormone. Conivaptan Hydrochloride is used for treatment of congestive heart failure.
- TPEN
Catalog No.:BCC7913
CAS No.:16858-02-9
- AIDA
Catalog No.:BCC6841
CAS No.:168560-79-0
- H-Asp(OMe)-OH.HCl
Catalog No.:BCC2889
CAS No.:16856-13-6
- Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium
Catalog No.:BCC4600
CAS No.:168555-66-6
- Dehydrogeijerin
Catalog No.:BCN7531
CAS No.:16850-91-2
- Z-D-Val-OH
Catalog No.:BCC2732
CAS No.:1685-33-2
- SHU 9119
Catalog No.:BCC6019
CAS No.:168482-23-3
- Epifriedelanol
Catalog No.:BCN1104
CAS No.:16844-71-6
- Rhodiocyanoside A
Catalog No.:BCN7852
CAS No.:168433-86-1
- Compound 401
Catalog No.:BCC7622
CAS No.:168425-64-7
- Tacrine hydrochloride
Catalog No.:BCC6869
CAS No.:1684-40-8
- Oxymatrine
Catalog No.:BCN1103
CAS No.:16837-52-8
- Ezatiostat
Catalog No.:BCC3638
CAS No.:168682-53-9
- H-Tyr-OtBu
Catalog No.:BCC3128
CAS No.:16874-12-7
- SGC707
Catalog No.:BCC6543
CAS No.:1687736-54-4
- Z-Tyr(tBu)-OH.DCHA
Catalog No.:BCC2745
CAS No.:16879-90-6
- RS 67333 hydrochloride
Catalog No.:BCC5693
CAS No.:168986-60-5
- RS 67506 hydrochloride
Catalog No.:BCC6878
CAS No.:168986-61-6
- Tropanyl phenylacetate
Catalog No.:BCN1927
CAS No.:1690-22-8
- 4'-O-Methylcoumestrol
Catalog No.:BCN7226
CAS No.:1690-62-6
- (2R,4R)-APDC
Catalog No.:BCC6969
CAS No.:169209-63-6
- MSPG
Catalog No.:BCC6819
CAS No.:169209-64-7
- MPPG
Catalog No.:BCC6818
CAS No.:169209-65-8
- MTPG
Catalog No.:BCC6820
CAS No.:169209-66-9
New drugs 07, part I.[Pubmed:17273084]
Nursing. 2007 Feb;37(2):51-8; quiz 59-60.
In this article, you'll learn about 13 new drugs, including: insulin glulisine and insulin detemir, both human insulin analogues; ranolazine, the first drug approved to treat chronic angina in more than a decade; Conivaptan HCl, the first drug approved to treat hyponatremia in patients with normal fluid balance. Unless otherwise specified, the information in the following summaries applies to adults, not children. Consult the package insert for information about each drug's safety during pregnancy and breast-feeding. Also consult the package insert, a pharmacist, or a comprehensive drug reference for more details on precautions, drug interactions, and adverse reactions for all these drugs.
